Background and Purpose — According to World Health Organization statistics, Ukraine has extremely high stroke mortality. No population-based prospective studies of stroke incidence have been performed yet in this European country with ≈50 million inhabitants. High reported rates of stroke mortality in official statistics conflict with some locally published incidence data in Ukraine. To obtain accurate data, we evaluated stroke incidence and 30-day case fatality in a prospective population study in the West Ukrainian city of Uzhgorod with a population of 126 000 inhabitants. Methods — Case certification by neurologists and follow-up at 30 days after stroke for all patients identified by any level of the health service system were performed for a 12-month period. Results — We identified 352 stroke cases. The age-standardized incidence was 341 and 238 of 100 000 and mortality was 83 and 69 of 100 000 with the use of the European or world standard population for standardization. Mean age of stroke patients was 63.4±12.5 years. Rate of hospitalization was 66%. Hospitalized patients were >10 years younger than those treated in their homes. The 30-day case fatality rates were 15.4% among hospitalized patients and 36.8% among those treated at home. Overall 30-day case fatality was 23.3%. Conclusions — Stroke incidence and 30-day case fatality in this West Ukrainian city were similar to those of some West European countries and were much lower than what could be expected from World Health Organization statistics. The relatively low incidence rate seems accurate; because of the organization of local stroke services, it is not probable that a considerable proportion of patients with acute stroke could bypass all levels of the acute care health system. Local health statistics reported a much lower number of stroke cases and stroke deaths than found in our survey; thus, further study is needed to clarify the reason for the discrepancy between local data and the high reported stroke mortality in Ukraine.
Background: The main goal of this collaborative effort is to provide genome-wide data for the previously underrepresented population in Eastern Europe, and to provide cross-validation of the data from genome sequences and genotypes of the same individuals acquired by different technologies. We collected 97 genome-grade DNA samples from consented individuals representing major regions of Ukraine that were consented for public data release. BGISEQ-500 sequence data and genotypes by an Illumina GWAS chip were cross-validated on multiple samples and additionally referenced to 1 sample that has been resequenced by Illumina NovaSeq6000 S4 at high coverage. Results: The genome data have been searched for genomic variation represented in this population, and a number of variants have been reported: large structural variants, indels, copy number variations, single-nucletide polymorphisms, and microsatellites. To our knowledge, this study provides the largest to-date survey of genetic variation in Ukraine, creating a public reference resource aiming to provide data for medical research in a large understudied population. Conclusions: Our results indicate that the genetic diversity of the Ukrainian population is uniquely shaped by evolutionary and demographic forces and cannot be ignored in future genetic and biomedical studies. These data will contribute a wealth of new information bringing forth a wealth of novel, endemic and medically related alleles.
1 January 2014 in Journal of Stroke and Cerebrovascular Diseases
Conflicts and natural disasters affect entire populations of the countries involved and, in addition to the thousands of lives destroyed, have a substantial negative impact on the scientific advances these countries provide. The unprovoked invasion of Ukraine by Russia, the devastating earthquake in Turkey and Syria, and the ongoing conflicts in the Middle East are just a few examples. Millions of people have been killed or displaced, their futures uncertain. These events have resulted in extensive infrastructure collapse, with loss of electricity, transportation, and access to services. Schools, universities, and research centers have been destroyed along with decades’ worth of data, samples, and findings. Scholars in disaster areas face short- and long-term problems in terms of what they can accomplish now for obtaining grants and for employment in the long run. In our interconnected world, conflicts and disasters are no longer a local problem but have wide-ranging impacts on the entire world, both now and in the future. Here, we focus on the current and ongoing impact of war on the scientific community within Ukraine and from this draw lessons that can be applied to all affected countries where scientists at risk are facing hardship. We present and classify examples of effective and feasible mechanisms used to support researchers in countries facing hardship and discuss how these can be implemented with help from the international scientific community and what more is desperately needed. Reaching out, providing accessible training opportunities, and developing collaborations should increase inclusion and connectivity, support scientific advancements within affected communities, and expedite postwar and disaster recovery.
Гліобластома є найбільш агресивним типом пухлини головного мозку, визначена як астроцитома 4-го типу відповідно до 5-го видання класифікації пухлин центральної нервової системи Всесвітньої організації охорони здоров’я. Це рак, що починається в гліальних клітинах, які є підтримуючими клітинами мозку. Гліобластома є рідкісним типом пухлини головного мозку і становить близько 15 % усіх цих пухлин. Найчастіше вона зустрічається в дорослих віком понад 50 років, причому в чоловіків розвивається частіше, ніж у жінок. Симптоми гліобластоми можуть відрізнятися залежно від локалізації пухлини в головному мозку. Загальні симптоми включають головний біль, нудоту, блювання та зміни зору. Іншими симптомами можуть бути судоми, зміни в поведінці або особистості, а також труднощі з мовою або рухами. Стандартом лікування гліобластоми є поєднання хірургічного втручання, променевої та хіміотерапії. Хірургічне втручання є першим кроком у лікуванні, метою якого є видалення якомога більшої частини пухлини. Променева та хіміотерапія зазвичай використовуються для знищення будь-яких залишкових ракових клітин. Однак, незважаючи на ці методи лікування, прогноз при гліобластомі, як правило, поганий, більшість пацієнтів живуть менше двох років після встановлення діагнозу. Загалом гліобластома є дуже агресивною пухлиною головного мозку з поганим прогнозом. Стандартне лікування передбачає поєднання хірургічного втручання, променевої та хіміотерапії. Останні дослідження були зосереджені на розробці нових методів лікування, таких як цільова терапія та імунотерапія, що показали обнадійливі результати в клінічних випробуваннях.